Shopping Cart 0
Cart Subtotal
USD 0

Epigenomics AG (ECX) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company's molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics' pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.

Epigenomics AG (ECX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Epigenomics AG, Medical Equipment, Deal Details 11

Partnerships 11

Biochain Institute Enters into Licensing Agreement with Epigenomics 11

Epigenomics And BioChain Expand Licensing Agreement For Septin9 12

Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13

Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14

Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15

Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16

Equity Offering 17

Epigenomics to Raise Funds Through Rights Offering of Shares 17

Epigenomics Raises USD6.5 Million in Private Placement of Shares 18

Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19

Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20

Epigenomics Raises USD5.3 Million in Private Placement of Shares 21

Epigenomics Completes Private Placement Of Shares For USD 4.5 Million 23

Epigenomics Announces Private Placement Of Shares For USD 1.3 Million 24

Epigenomics Completes Rights Issue Of Common Stock For USD 6 Million 25

Epigenomics Completes Private Placement Of Shares For USD 0.7 Million 26

Debt Offering 27

Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27

Epigenomics Announces Private Placement Of Bonds For USD 6.7 Million 28

Acquisition 29

Cathay Fortune International to Acquire Epigenomics 29

Epigenomics AG-Key Competitors 31

Epigenomics AG-Key Employees 32

Epigenomics AG-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Aug 08, 2018: Epigenomics Announces 2018 Second Quarter and Six Month Financial Results 34

May 09, 2018: Epigenomics announces 2018 First Quarter Financial Results 35

Mar 23, 2018: Epigenomics Reports Results for Financial Year 2017 36

Nov 15, 2017: Epigenomics Announces 2017 Third Quarter and Nine Months Financial Results 38

Aug 09, 2017: Epigenomics Announces 2017 Second Quarter and Six Months Financial Results 39

Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 40

May 10, 2017: Epigenomics announces 2017 First Quarter Financial Results 41

Apr 26, 2017: Epigenomics Reports Results for Financial Year 2016 42

Corporate Communications 43

Nov 29, 2017: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand) 43

Nov 08, 2017: Epigenomics Appointment of Director Reimbursement and Medical Affairs 44

Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Epigenomics AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Epigenomics AG, Medical Equipment, Key Facts, 2017 2

Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Epigenomics AG, Deals By Market, 2012 to YTD 2018 9

Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Biochain Institute Enters into Licensing Agreement with Epigenomics 11

Epigenomics And BioChain Expand Licensing Agreement For Septin9 12

Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13

Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14

Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15

Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16

Epigenomics to Raise Funds Through Rights Offering of Shares 17

Epigenomics Raises USD6.5 Million in Private Placement of Shares 18

Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19

Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20

Epigenomics Raises USD5.3 Million in Private Placement of Shares 21

Epigenomics Completes Private Placement Of Shares For USD 4.5 Million 23

Epigenomics Announces Private Placement Of Shares For USD 1.3 Million 24

Epigenomics Completes Rights Issue Of Common Stock For USD 6 Million 25

Epigenomics Completes Private Placement Of Shares For USD 0.7 Million 26

Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27

Epigenomics Announces Private Placement Of Bonds For USD 6.7 Million 28

Cathay Fortune International to Acquire Epigenomics 29

Epigenomics AG, Key Competitors 31

Epigenomics AG, Key Employees 32

Epigenomics AG, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Epigenomics AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.